The European Union (EU) is at the forefront of discussions regarding the regulation of products derived from New Genomic Techniques (NGTs), such as CRISPR-Cas9. GeneBEcon through this policy brief aims to provide insights into key regulatory, technical, social, and ethical considerations relevant to the ongoing EU discourse. Drawing upon the comprehensive report published by GeneBEcon, this brief offers guidance for policymakers, developers, and stakeholders involved in shaping the regulatory landscape for NGT products within the EU.

This Policy Brief is based on an extensive report by GeneBEcon, read more here.

Read “GeneBEcon Policy Brief – New Genomic Techniques Policy Directions” here. 

Read the Press Release here.